September 2016
Volume 57, Issue 12
Open Access
ARVO Annual Meeting Abstract  |   September 2016
Clinical effectiveness of the fluocinolone acetonide implant in diabetic macular oedema resistant to anti-VEGF therapy
Author Affiliations & Notes
  • Spyridon E Chalkiadakis
    Ophthalmology, University Of Surrey, Guildford, United Kingdom
    Ophthalmology, Royal Surrey County Hospital, Guilford, United Kingdom
  • Fiona J Harris
    Ophthalmology, University Of Surrey, Guildford, United Kingdom
    Ophthalmology, Royal Surrey County Hospital, Guilford, United Kingdom
  • Simon Taylor
    Ophthalmology, University Of Surrey, Guildford, United Kingdom
    Ophthalmology, Royal Surrey County Hospital, Guilford, United Kingdom
  • Footnotes
    Commercial Relationships   Spyridon Chalkiadakis, None; Fiona Harris, None; Simon Taylor, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science September 2016, Vol.57, 3258. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Spyridon E Chalkiadakis, Fiona J Harris, Simon Taylor; Clinical effectiveness of the fluocinolone acetonide implant in diabetic macular oedema resistant to anti-VEGF therapy. Invest. Ophthalmol. Vis. Sci. 2016;57(12):3258.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Intravitreal corticosteroid implants may be useful in treating diabetic macular oedema (DMO) refractive to standard therapies. FAME study for the fluocinolone acetonide (ILUVIEN®) implant recruited a few patients who had prior exposure to anti-VEGF therapy. We therefore performed a prospective observational study of the clinical effectiveness of intravitreal ILUVIEN implant in patients with DMO, unresponsive to conventional anti-VEGF therapy.

Methods : We performed a prospective observational study regarding the outcomes and side-effects in 26 eyes of 24 consecutive patients with DMO refractory to ranibizumab intravitreal injections, who were treated with the 0.19 µg Iluvien implant. All patients were pseudophakic at baseline. DMO was categorised into chronic (≥36 months) or non-chronic (<36 months).

Results : After 9 months, 50% of both the chronic and non-chronic DMO groups gained ≥15 letters from baseline; the mean letter gains being +10.3 letters in the non-chronic DMO group and +20.5 letters in the chronic DMO group. The average Central Retinal Thicknesses (CRT) were 335 µm in the non-chronic DMO group and 375µm in the chronic DMO group - a decrease from baseline of 41 µm and 127 µm respectively. By month 9, 5/26 patients had raised intraocular pressure (IOP), requiring IOP-lowering medication; the IOP rises were similar in each group, at 7-8 mm Hg.

Conclusions : Patients with chronic DMO gained more letters on the ETDRS chart and had a greater reduction in CRT, on average, than those with DMO of less than 36 months’ standing. Nevertheless, both groups of patients responded well to the ILUVIEN implant despite being refractory to treatment with ranibizumab. The rate of raised IOP requiring treatment was approximately 20%.

This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×